Lessons Learned From PEPFARDYBUL, Mark.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, issn 1525-4135, S12-S13, SUP1Article

Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parametersDYBUL, Mark; NIES-KRASKE, Elizabeth; HIDALGO, Bertha et al.The Journal of infectious diseases. 2003, Vol 188, Num 3, pp 388-396, issn 0022-1899, 9 p.Article

Evaluation of initial CD4⁺ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settingsDYBUL, Mark; BOLAN, Robert; HIDALGO, Bertha et al.The Journal of infectious diseases. 2002, Vol 185, Num 12, pp 1818-1821, issn 0022-1899Article

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysisCREMIN, Ide; ALSALLAQ, Ramzi; DYBUL, Mark et al.AIDS (London). 2013, Vol 27, Num 3, pp 447-458, issn 0269-9370, 12 p.Article

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: The Panel on Clinical Practices for Treatment of HIVDYBUL, Mark; FAUCI, Anthony S; BARTLETT, John G et al.Annals of internal medicine. 2002, Vol 137, Num 5, pp 381-433, issn 0003-4819, 2Article

Developing an evidence-based, preventive care package for persons with HIV in AfricaMERMIN, Jonathan; BUNNELL, Rebecca; LULE, John et al.TM & IH. Tropical medicine & international health. 2005, Vol 10, Num 10, pp 961-970, issn 1360-2276, 10 p.Article

Le Fonds mondial de lutte contre le sida, la tuberculose et le paludismeBRISSET, Claire; CANFIN, Pascal; COLOMA, Tristan et al.Le Monde diplomatique (Paris. 1954). 2013, Num 711, pp 1-4, issn 0026-9395, 4 p., SupplArticle

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infectionDYBUL, Mark; NIES-KRASKE, Elizabeth; METCALF, Julia A et al.The Journal of infectious diseases. 2004, Vol 189, Num 11, pp 1974-1982, issn 0022-1899, 9 p.Article

Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination preventionJONES, Alexandra; CREMIN, Ide; SCHWARTLANDER, Bernhard et al.Lancet (British edition). 2014, Vol 384, Num 9939, pp 272-279, issn 0140-6736, 8 p.Article

Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment ProgramsHOLMES, Charles B; COGGIN, William; DYBUL, Mark et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 3, pp 313-320, issn 0098-7484, 8 p.Article

Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling studyANDERSON, Sarah-Jane; CHERUTICH, Peter; DYBUL, Mark et al.Lancet (British edition). 2014, Vol 384, Num 9939, pp 249-256, issn 0140-6736, 8 p.Article

The United States President's Emergency Plan for AIDS Relief: A Story of Partnerships and Smart Investments to Turn the Tide of the Global AIDS PandemicGOOSBY, Eric; DYBUL, Mark; FAUCI, Anthony A et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, issn 1525-4135, S51-S56, SUP3Article

Evaluation of the Pathogenesis of Decreasing CD4⁺ T Cell Counts in Human Immunodeficiency Virus Type 1―Infected Patients Receiving Successfully Suppressive Antiretroviral TherapyNIES-KRASKE, Elizabeth; SCHACKER, Timothy W; GUENAGA, Javier et al.The Journal of infectious diseases. 2009, Vol 199, Num 11, pp 1648-1656, issn 0022-1899, 9 p.Article

Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysisDRUYTS, Eric; DYBUL, Mark; MILLS, Edward J et al.AIDS (London). 2013, Vol 27, Num 3, pp 417-425, issn 0269-9370, 9 p.Article

Association of aging and survival in a large HIV-infected cohort on antiretroviral therapyBAKANDA, Celestin; BIRUNGI, Josephine; DYBUL, Mark et al.AIDS (London). 2011, Vol 25, Num 5, pp 701-705, issn 0269-9370, 5 p.Article

Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From UgandaMILLS, Edward J; BAKANDA, Celestin; BIRUNGI, Josephine et al.Annals of internal medicine. 2011, Vol 155, Num 4, pp 209-216, issn 0003-4819, 8 p.Article

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in UgandaREYNOLDS, Steven J; KITYO, Cissy; MBAMANYA, Frank et al.Antiviral therapy (London). 2009, Vol 14, Num 2, pp 293-297, issn 1359-6535, 5 p.Article

HIV preferentially infects HIV-specific CD4⁺ T cellsDOUEK, Daniel C; BRENCHLEY, Jason M; GROSSMAN, Zvi et al.Nature (London). 2002, Vol 417, Num 6884, pp 95-98, issn 0028-0836Article

Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infectionDYBUL, Mark; HIDALGO, Bertha; METCALF, Julia A et al.The Journal of infectious diseases. 2002, Vol 185, Num 1, pp 61-68, issn 0022-1899Article

Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infectionPOWERS, April E; MARDEN, Susan F; ROSE MCCONNELL, L. C. D. R et al.AIDS (London). 2006, Vol 20, Num 6, pp 837-845, issn 0269-9370, 9 p.Article

Virological Outcome after Structured Interruption of Antiretroviral Therapy for Human Immunodeficiency Virus Infection Is Associated with the Functional Profile of Virus-Specific CD8⁺ T CellsDAUCHER, Marybeth; PRICE, David A; GUMKOWSKI, Julie et al.Journal of virology. 2008, Vol 82, Num 8, pp 4102-4114, issn 0022-538X, 13 p.Article